n/a
Abstract Title:

Astragaloside IV attenuates TGF-β-mediated epithelial-mesenchymal transition of pulmonary fibrosis via suppressing NLRP3 expression.

Abstract Source:

Pharmazie. 2021 Feb 25 ;76(2):97-102. PMID: 33714286

Abstract Author(s):

Yan Hou, Yingli Zhen, Qingliang Xue, Wei Wang

Article Affiliation:

Yan Hou

Abstract:

Pulmonary fibrosis (PF) is a severe chronic disease. Although astragaloside IV (ASV) is known to have therapeutic effects on PF, the therapeutic targets of ASV require further study. This study was designed to elucidate the regulatory effect of ASV on PF via NLRP3. PF was triggered by transforming growth factor-β (TGF-β). The relative activity of TGF-β was measured by luciferase reporter assay. Protein levels were determined by western blotting assay. The NLRP3 expression was analyzed using immunofluorescence analysis. mRNA levels were detected by qRT-PCR. MTT assay was performed to determine cell viability. Wound healing and transwell assays were conducted to investigate cell migration and invasion. We found that ASV markedly suppressed TGF-β activity, Smad2/3 and NLRP3 protein expression levels. ASV inhibited cell viability, migration and invasion ability. Moreover, ASV mediated downregulation of N-cadherin and Snail and upregulation of E-cadherin, which further suppressed the epithelial-mesenchymal transition (EMT). However, overexpression of NLRP3 reversed the effects of ASV and promoted Collagen I, Collagen II and α-SMA protein expressions. In conclusion, ASV efficiently retarded PF progress via suppressing NLRP3 expression.

Study Type : In Vitro Study

Print Options


Key Research Topics

This website is for information purposes only. By providing the information contained herein we are not diagnosing, treating, curing, mitigating, or preventing any type of disease or medical condition. Before beginning any type of natural, integrative or conventional treatment regimen, it is advisable to seek the advice of a licensed healthcare professional.

© Copyright 2008-2024 GreenMedInfo.com, Journal Articles copyright of original owners, MeSH copyright NLM.